Literature DB >> 11038245

Effects of post-mortem delay on subunits of ionotropic glutamate receptors in human brain.

Y Wang1, E TesFaye, R P Yasuda, D C Mash, D M Armstrong, B B Wolfe.   

Abstract

The effect of post-mortem delay on the stability of the protein subunits that combine to form NMDA and AMPA type glutamate receptors has been assessed in samples of human brain tissue. While most of the subunits (i.e. GluR1, GluR2/3, GluR4, NR1) appear to be stable for up to 18 h post-mortem, the NR2A and NR2B subunits appear to be proteolyzed rapidly following death. These results are consistent with the concept that the proteolytic products of NR2A and NR2B, although at smaller molecular sizes than the full-length protein, are all identifiable on Western blots. Thus, a method is proposed that allows for the estimation of the levels of these labile proteins even in samples obtained up to 18 h post-mortem. Using this method we have estimated the levels of all AMPA and NMDA receptor subunits in selected (i.e. hippocampus, frontal and entorhinal cortex) brain tissue samples obtained from control patients and patients who have died with Alzheimer's disease. Modest decreases in NMDA receptor subunits NR1, NR2A, and NR2B were found in the hippocampus and in frontal cortex while little or no change in any of these subunits were documented in entorhinal cortex. Subunits for AMPA receptors (GluR1, GluR2/3, and GluR4) appeared to show a generalized decrease in all these tissues. As a surrogate marker for overall decreases due to generalized neuronal cell death, levels of neuron-specific enolase were measured in all tissues and were found to be nearly identical in control and Alzheimer's brains.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11038245     DOI: 10.1016/s0169-328x(00)00111-x

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  9 in total

1.  Fear memory impairing effects of systemic treatment with the NMDA NR2B subunit antagonist, Ro 25-6981, in mice: attenuation with ageing.

Authors:  Poonam Mathur; Carolyn Graybeal; Michael Feyder; Margaret I Davis; Andrew Holmes
Journal:  Pharmacol Biochem Behav       Date:  2008-09-08       Impact factor: 3.533

2.  AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs.

Authors:  J A O'Connor; E C Muly; S E Arnold; S E Hemby
Journal:  Schizophr Res       Date:  2006-12-01       Impact factor: 4.939

3.  Properties of glutamate receptors of Alzheimer's disease brain transplanted to frog oocytes.

Authors:  Annalisa Bernareggi; Zulma Dueñas; Jorge Mauricio Reyes-Ruiz; Fabio Ruzzier; Ricardo Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-14       Impact factor: 11.205

4.  Molecular profiling of midbrain dopamine regions in cocaine overdose victims.

Authors:  Wen-Xue Tang; Wendy H Fasulo; Deborah C Mash; Scott E Hemby
Journal:  J Neurochem       Date:  2003-05       Impact factor: 5.372

5.  Developmental regulation of the NMDA receptor subunits, NR3A and NR1, in human prefrontal cortex.

Authors:  Maile A Henson; Adam C Roberts; Kayvon Salimi; Swarooparani Vadlamudi; Robert M Hamer; John H Gilmore; L Fredrik Jarskog; Benjamin D Philpot
Journal:  Cereb Cortex       Date:  2008-02-21       Impact factor: 5.357

6.  Impaired discrimination learning in mice lacking the NMDA receptor NR2A subunit.

Authors:  Jonathan L Brigman; Michael Feyder; Lisa M Saksida; Timothy J Bussey; Masayoshi Mishina; Andrew Holmes
Journal:  Learn Mem       Date:  2008-01-28       Impact factor: 2.460

Review 7.  Synaptic Reshaping and Neuronal Outcomes in the Temporal Lobe Epilepsy.

Authors:  Elisa Ren; Giulia Curia
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

8.  Human post-mortem synapse proteome integrity screening for proteomic studies of postsynaptic complexes.

Authors:  Àlex Bayés; Mark O Collins; Clare M Galtrey; Clémence Simonnet; Marcia Roy; Mike D R Croning; Gemma Gou; Louie N van de Lagemaat; David Milward; Ian R Whittle; Colin Smith; Jyoti S Choudhary; Seth G N Grant
Journal:  Mol Brain       Date:  2014-11-28       Impact factor: 4.041

9.  Metabotropic glutamate receptor 3 (mGlu3; mGluR3; GRM3) in schizophrenia: Antibody characterisation and a semi-quantitative western blot study.

Authors:  Aintzane García-Bea; Mary A Walker; Thomas M Hyde; Joel E Kleinman; Paul J Harrison; Tracy A Lane
Journal:  Schizophr Res       Date:  2016-04-27       Impact factor: 4.939

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.